Nutra Pharma Corp. operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. Additionally, the company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.
Interview on NBC News - Miami
NBC News - Miami aired an interview with CEO, Rik Deitsch discussing the use of cobra venom for the treatment of pain. The interview can be viewed on the following link: View
Nutra Pharma Featured on Univision's Spanish-language New's Show - Primer Impacto
Nutra Pharma's over the counter (OTC) products, Nyloxin and Pet Pain-Away, were featured on Univision's Spanish-language news show, Primer Impacto on June 6, 2017. The interview can be viewed on the following link: View
Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin®, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Nyloxin® is protected under patent #7,902,152, Use of cobratoxin as an analgesic. In December of 2014, the Company launched Pet Pain-Away - the first OTC product to treat pain in companion animals without side effects.
The Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Nutra Pharma has completed pre-clinical and animal models for their MS and HIV applications and are preparing to move into pivotal Phase II trials. Nutra Pharma's MS drug was recently granted Orphan Status by the FDA for the treatment of Pediatric Multiple Sclerosis.